Aspirin use is associated with an improved long-term survival in an unselected population presenting with unstable angina

Clinical Cardiology

Volumn 33, Issue 9, 2010, Pages 553-558

  Razzouk, Louai ^a   Mathew, Verghese ^b   Lennon, Ryan J ^b   Aneja, Ashish ^c   Mozes, Joshua I ^d   Wiste, Heather J ^b   Muntner, Paul ^e   Chesebro, James H ^f   Farkouh, Michael E ^g  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Mayo Clinic College of Medicine   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f UMASS MEMORIAL MEDICAL CENTER   (United States)

^g UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG USE; EMERGENCY WARD; FEMALE; FOLLOW UP; HEART INFARCTION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; OUTCOME ASSESSMENT; RISK REDUCTION; STROKE; SURVIVAL; UNITED STATES; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; AGED; ASPIRIN; CONFIDENCE INTERVALS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MINNESOTA; MULTIVARIATE ANALYSIS; PATIENT DISCHARGE; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 77956946776     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20769     Document Type: Article

References (19)

1. Vane JR, Botting RM. The mechanismof action of aspirin. Thromb Res. 2003;110:255-258.
2. Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest. 1978;61:314-319. (Pubitemid 8280401)
3. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group. Lancet. 1990;336:827-830.
4. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116:e148-e304.
5. Grapow MT, von Wattenwyl R, Guller U, et al. Randomized controlled trials do not reflect reality: real-world analyses are critical for treatment guidelines! J Thorac Cardiovasc Surg. 2006;132:5-7. (Pubitemid 43913875)
6. Willenheimer R. Statistical significance versus clinical relevance in cardiovascular medicine. Prog CardiovascDis. 2001;44:155-167. (Pubitemid 33117026)
7. Hennekens CH, Karlson LK, Rosner B. A case-control study of regular aspirin use and coronary deaths. Circulation. 1978;58:35-38.
8. The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group. Circulation. 1980;62(6 pt 2):V79-V84.
9. Persantine and aspirin in coronary heart disease. The Persantine- Aspirin Reinfarction Study Research Group. Circulation. 1980;62:449-461.
10. Hennekens CH, Buring JE, Sandercock P, et al. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation. 1989;80:749-756. (Pubitemid 19261621)
11. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
12. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284:835-842.
13. Borzak S, Cannon CP, Kraft PL, et al. Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia. Am J Cardiol. 1998;81:678-681.
14. Alexander JH, Harrington RA, Tuttle RH, et al. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Am J Cardiol. 1999;83:1147-1151.
15. Baigent C, Collins R, Appleby P, et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ. 1998;316:1337-1343.
16. Capewell S, Murphy NF, MacIntyre K, et al. Short-term and long term outcomes in 133,429 emergency patients admitted with angina or myocardial infarction in Scotland, 1990-2000: population-based cohort study. Heart. 2006;92:1563-1570.
17. Simpson E, Beck C, Richard H, et al. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J. 2003;145:438-444. (Pubitemid 36390489)
18. Frilling B, Schiele R, Gitt AK, et al. Too little aspirin for secondary prevention after acute myocardial infarction in patients at high risk for cardiovascular events: results from the MITRA study. Am Heart J. 2004;148:306-311.
19. Krumholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. Ann Intern Med. 1996;124:292-298.